The 7 Best Technologies Of The Colour Television

TV News Report reveals disturbing new information on recoveries of Trasylol

On February 17, 2008, the television program 60 Research minutes aired a segment on prescription drug aprotinin, marketed by Bayer Trasylol. In the report, we are given the sordid history of 14 years drugs; concerns before the Food and Drug Association (FDA), an aggressive marketing campaign during the first years of its introduction in the market, many deaths resulting from the common side effects Trasylol.

As for the 1980s, concern about potentially fatal side effects of Trasylol were discussed. Dr. Juergen Fischer, director of the Institute of Experimental Medicine University of Cologne, found serious incidents of kidney damage in animals given Trasylol. When he sent the results of their investigations Bayer, considered the information, giving Trayslol deadly side effects. Soon after, side effects have demonstrated in similar patients receiving the drug in U.S. hospitals.

The most common side effects Trayslol was acute renal failure, also known as acute renal failure as a result of kidney damage.

Continued use is prudent, Dr. Nicholas Kouchoukos, one of the heart surgeons "America's Top conducted a small study of 20 patients who received Trasylol. Among those who received the drug, 13 had function problems kidney after taking the drug. Ignoring these results and several other similar studies, the FDA approved the use of Trasylol in 1993.

Thanks to a relentless marketing campaign and intense pressure on the FDA, Bayer had cornered the market almost on the use of Trasylol ® in all open heart surgeries, and was the drug of choice to control bleeding in the other major surgery. The drug sales reached $ 300 million in 2005, with projected sales of $ 750 million 2006.

Dr. Dennis Mangano, a boss in the field of medical research, concluded a study at the same time, a study that track records of 5065 patients in 17 countries from Trayslol. Published in the New England Journal of Medicine in January 2006, was the largest Trasylol study ever conducted, and ultimately the most enlightening, not only suggests an association between patients receiving Trasylol and acute renal failure, but also a tendency at greater risk of hospital death.

When Dr. Mangano presented his findings at an FDA advisory committee, the reaction has been less dynamic than what had imagined. Since the results of Dr. Mangano was based on hospital records of patients rather than a more traditional involvement of a placebo, the committee reluctant to comply with your request to withdraw the drug from the market.

Without knowledge of the commission Bayer had the results of a study conducted by the hired Harvard professor Dr. Alexander Walker, who examined records of nearly 70,000 patients in the same way that Mr. Mangano has done his research. More surprising results were strikingly similar study Dr. Walker has found: patients receiving Trasylol were at greater risk of acute renal failure and death.

Bayer did not report confirming the results of the panel headed by Mr Walker in contact with the FDA, emphasizing the fact that Bayer had deliberately concealed potentially overwhelming information to continue selling profitable Trayslol. However, the only response from the FDA for the confirmation of the deadly side effects has been warning other doctors would be a full year before the committee will meet again to reassess the effectiveness of the drug.

While Therefore, a clinical term in Canada in 2007 was interrupted when the participants in the study group began to die. The German government immediately removed and banned Trayslol, through a joint effort between the Government of Canada and the FDA, Bayer has been persuaded to a temporary suspension from the continued marketing of drugs fatal.

An estimated 4.5 million people have been in Trayslol the world, one third of these patients, approximately 1.5 million people have received the drug to United States within 14 years, the drug has been available. According to estimates by Dr. Mangano, While in the short time between his studies and the temporary moratorium on the latest drug, the drug was withdrawn from the market, could have saved over 22,000 lives – about 1,000 people each month.

About the Author

Visit http://www.LegalView.com to learn about a variety of legal topics, legal information and jury verdicts on these related topics. Find information on traumatic brain injury at http://brain-injury.legalview.com or learn how to contact an auto accident law firm at http://crash.legalview.com/ .

The Most Uncomfortable Segment in TV News History